ReviewPharmaceuticals (Basel, Switzerland)2024
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.
Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Pooled it
- Finerenone attenuates chronic fibrotic remodeling during the AKI-CKD transition in an ischemia-reperfusion-induced acute kidney injury mouse model.Renal failure · 2026Article
- Cardiorenal Protective Effects of Finerenone in Patients with Type 2 Diabetes Mellitus.Archives of internal medicine research · 2026Article
- CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.Cardiovascular diabetology · 2026Article
- Review
- Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review.Biomedicines · 2026Review
- Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Review
- Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia.PloS one · 2026Article
- Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives.Kidney & blood pressure research · 2026Review
- CKDs at the Crossroads: From Failures to Future Therapies.Kidney international reports · 2025Review
- How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy.Frontiers in immunology · 2025Review
- Predictive value of serum uric acid-to-albumin ratio for diabetic kidney disease in patients with type 2 diabetes mellitus: a case-control study.Frontiers in endocrinology · 2025Article
- Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study.Metabolism open · 2024Article
- Review
- A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children.Children (Basel, Switzerland) · 2024Review
- A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist used for treating diabetic kidney disease. It has predominant anti-fibrotic and anti-inflammatory effects and exhibits several renal and cardiac protective effects. This review article summarizes the current knowledge and future prospects of finerenone in treating patients with kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.